Supriya Lifescience (NSE:SUPRIYA) Stock Based Compensation: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SUPRIYA Supriya Lifescience Ltd NSE:SUPRIYA
80 GF Score
Price ₹831.05
GF Value ₹825.83
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Supriya Lifescience Stock Based Compensation?

Supriya Lifescience NSE:SUPRIYA -2.34% 80 Stock Based Compensation is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:SUPRIYA with a GF Score™ of 80/100 and a GF Value™ of ₹825.83 (Fairly Valued). The stock has 8 warning signs investors should review.

Supriya Lifescience's Stock Based Compensation for the three months ended in Mar. 2026 was ₹0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Supriya Lifescience Stock Based Compensation Related Terms

Supriya Lifescience Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Supriya Lifescience's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supriya Lifescience Stock Based Compensation Chart

Supriya Lifescience Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Supriya Lifescience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SUPRIYA
80GF Score
Supriya Lifescience Ltd NSE:SUPRIYA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supriya Lifescience Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

What does a Stock Based Compensation of ₹0 Mil mean?
Supriya Lifescience (NSE:SUPRIYA) has a Stock Based Compensation of ₹0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Supriya Lifescience and its competitors.
Is Supriya Lifescience's Stock Based Compensation too high?
Supriya Lifescience's current Stock Based Compensation is ₹0 Mil. Overall, Supriya Lifescience has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supriya Lifescience's Stock Based Compensation compare to VRTX and REGN?
Supriya Lifescience's Stock Based Compensation of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Supriya Lifescience and its competitors. Supriya Lifescience's current Stock Based Compensation is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supriya Lifescience stock overvalued right now?
Based on GuruFocus' analysis, Supriya Lifescience (NSE:SUPRIYA) is currently considered Fairly Valued. The stock's GF Value™ is ₹825.83, compared to a current price of ₹831.05 — trading 0.6% above its estimated fair value. The current Stock Based Compensation is ₹0 Mil. Supriya Lifescience's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Supriya Lifescience (NSE:SUPRIYA), the current Stock Based Compensation is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supriya Lifescience (NSE:SUPRIYA) Overvalued in 2026?

Based on GuruFocus' analysis, Supriya Lifescience stock appears to be overvalued. The current stock price of ₹831.05 is trading 0.6% above its estimated GF Value™ of ₹825.83. GuruFocus considers Supriya Lifescience to be Fairly Valued.

Key valuation signals for NSE:SUPRIYA:

  • Stock Based Compensation: ₹0 Mil
  • GF Value™: ₹825.83 vs. price of ₹831.05 (0.6% above fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the NSE:SUPRIYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supriya Lifescience Business Description

Other Exchanges 543434:India
Address Sonawala Road, 207/208, Udyog Bhavan, Goregaon East, Mumbai, MH, IND, 400063
Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.
80GF Score

Get the complete analysis for NSE:SUPRIYA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹831.05
Price
₹825.83
GF Value